Completed Studies:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of GalNAc-conjugated FXI Antisense Oligonucleotide in Patients with End-Stage Renal Disease on Hemodialysis.
Multi-center Cross-sectional Epidemiological Study to Characterize the Prevalence and Distribution of Lipoprotein(a) Levels Among Patients with Established Cardiovascular Disease.
A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 with Background Treatment in Subjects with Lupus Nephritis.
GSK 205270 – A 28-week, randomized, double-blind, placebo-controlled, parallel group, multi-center, study in recombinant human erythropoietin (rhEPO) naive non-dialysis participants with anemia associated with chronic kidney disease to evaluate the efficacy, safety and effects on quality of life of daprodustat compared to placebo.